“I’m very proud and happy about this study because it is science — we did things the way they should be done,” the study’s lead investigator, Dr. Orrin Devinsky of the Comprehensive Epilepsy Center at New York University Langone Medical Center, said to the media. The study involved 120 patients with an average age of 10 and an average frequency of 13 convulsive seizures a month at the start of the study. The frequency of convulsive seizures fell by 39 percent during the 14-week treatment period for the patients who received Epidiolex. A few patients had troubles due to sides effects. That means drowsiness, diarrhea, decreased appetite, fatigue, fever, vomiting and upper respiratory infection. Dravet syndrome typically starts in infancy and affects about 5,000 children in the United States.